BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lingblom C, Bergquist H, Johnsson M, Sundström P, Quiding-Järbrink M, Bove M, Wennerås C. Topical corticosteroids do not revert the activated phenotype of eosinophils in eosinophilic esophagitis but decrease surface levels of CD18 resulting in diminished adherence to ICAM-1, ICAM-2, and endothelial cells. Inflammation 2014;37:1932-44. [PMID: 24870064 DOI: 10.1007/s10753-014-9926-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Lingblom C, Wallander J, Ingelsten M, Bergquist H, Bove M, Saalman R, Welin A, Wennerås C. Eosinophils from eosinophilic oesophagitis patients have T cell suppressive capacity and express FOXP3. Clin Exp Immunol 2017;187:455-65. [PMID: 27921303 DOI: 10.1111/cei.12898] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
2 Nhu QM, Aceves SS. Medical and dietary management of eosinophilic esophagitis. Ann Allergy Asthma Immunol 2018;121:156-61. [PMID: 29753831 DOI: 10.1016/j.anai.2018.05.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
3 Runge TM, Dellon ES. Do We Know What Causes Eosinophilic Esophagitis? A Mechanistic Update. Curr Gastroenterol Rep 2015;17:33. [PMID: 26205715 DOI: 10.1007/s11894-015-0458-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
4 Goyal A, Cheng E. Recent discoveries and emerging therapeutics in eosinophilic esophagitis. World J Gastrointest Pharmacol Ther 2016; 7(1): 21-32 [PMID: 26855809 DOI: 10.4292/wjgpt.v7.i1.21] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
5 Metcalfe DD, Pawankar R, Ackerman SJ, Akin C, Clayton F, Falcone FH, Gleich GJ, Irani AM, Johansson MW, Klion AD, Leiferman KM, Levi-Schaffer F, Nilsson G, Okayama Y, Prussin C, Schroeder JT, Schwartz LB, Simon HU, Walls AF, Triggiani M. Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organ J 2016;9:7. [PMID: 26904159 DOI: 10.1186/s40413-016-0094-3] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 12.2] [Reference Citation Analysis]
6 Hines BT, Rank MA, Wright BL, Marks LA, Hagan JB, Straumann A, Greenhawt M, Dellon ES. Minimally invasive biomarker studies in eosinophilic esophagitis: A systematic review. Ann Allergy Asthma Immunol 2018;121:218-28. [PMID: 29753832 DOI: 10.1016/j.anai.2018.05.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
7 O'Shea KM, Aceves SS, Dellon ES, Gupta SK, Spergel JM, Furuta GT, Rothenberg ME. Pathophysiology of Eosinophilic Esophagitis. Gastroenterology. 2018;154:333-345. [PMID: 28757265 DOI: 10.1053/j.gastro.2017.06.065] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 26.4] [Reference Citation Analysis]
8 Clayton F, Peterson K. Eosinophilic Esophagitis. Gastrointestinal Endoscopy Clinics of North America 2018;28:1-14. [DOI: 10.1016/j.giec.2017.07.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
9 Tytor J, Larsson H, Bove M, Johansson L, Bergquist H. Topically applied mometasone furoate improves dysphagia in adult eosinophilic esophagitis - results from a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 2021;56:629-34. [PMID: 33831327 DOI: 10.1080/00365521.2021.1906314] [Reference Citation Analysis]
10 Khoury P, Makiya M, Klion AD. Clinical and Biological Markers in Hypereosinophilic Syndromes. Front Med (Lausanne) 2017;4:240. [PMID: 29312946 DOI: 10.3389/fmed.2017.00240] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
11 Tiwary M, Rooney RJ, Liedmann S, LeMessurier KS, Samarasinghe AE. Eosinophil Responses at the Airway Epithelial Barrier during the Early Phase of Influenza A Virus Infection in C57BL/6 Mice. Cells 2021;10:509. [PMID: 33673645 DOI: 10.3390/cells10030509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Lingblom C, Käppi T, Bergquist H, Bove M, Arkel R, Saalman R, Wennerås C. Differences in eosinophil molecular profiles between children and adults with eosinophilic esophagitis. Allergy 2017;72:1406-14. [PMID: 28194801 DOI: 10.1111/all.13140] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
13 Nhu QM, Aceves SS. Tissue Remodeling in Chronic Eosinophilic Esophageal Inflammation: Parallels in Asthma and Therapeutic Perspectives. Front Med (Lausanne) 2017;4:128. [PMID: 28831387 DOI: 10.3389/fmed.2017.00128] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
14 Philpott H, Nandurkar S, Thien F, Gibson PR, Royce SG. Eosinophilic esophagitis: a clinicopathological review. Pharmacol Ther. 2015;146:12-22. [PMID: 25200122 DOI: 10.1016/j.pharmthera.2014.09.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
15 Cheng E. Translating new developments in eosinophilic esophagitis pathogenesis into clinical practice. Curr Treat Options Gastroenterol. 2015;13:30-46. [PMID: 25598233 DOI: 10.1007/s11938-014-0041-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
16 Blanchard C. Molecular pathogenesis of eosinophilic esophagitis. Curr Opin Gastroenterol 2015;31:321-7. [PMID: 26039724 DOI: 10.1097/MOG.0000000000000186] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]